相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Molecular Minimal Residual Disease in Acute Myeloid Leukemia
M. Jongen-Lavrencic et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia
Jacqueline Cloos et al.
JOVE-JOURNAL OF VISUALIZED EXPERIMENTS (2018)
Prognostic impact of the CD34+/CD38-cell burden in patients with acute myeloid leukemia receiving allogeneic stem cell transplantation
Madlen Jentzsch et al.
AMERICAN JOURNAL OF HEMATOLOGY (2017)
Therapeutic value of clofarabine in younger and middle-aged (18-65 years) adults with newly diagnosed AML
Bob Lowenberg et al.
BLOOD (2017)
A simple one-tube assay for immunophenotypical quantification of leukemic stem cells in acute myeloid leukemia
W. Zeijlemaker et al.
LEUKEMIA (2016)
Genetically distinct leukemic stem cells in human CD34- acute myeloid leukemia are arrested at a hemopoietic precursor-like stage
Lynn Quek et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2016)
A 17-gene stemness score for rapid determination of risk in acute leukaemia
Stanley W. K. Ng et al.
NATURE (2016)
Assessment of Minimal Residual Disease in Standard-Risk AML
A. Ivey et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Absence of leukaemic CD34+ cells in acute myeloid leukaemia is of high prognostic value: a longstanding controversy deciphered
Wendelien Zeijlemaker et al.
BRITISH JOURNAL OF HAEMATOLOGY (2015)
An immunophenotypic pre-treatment predictor for poor response to induction chemotherapy in older acute myeloid leukaemia patients: blood frequency of CD34+CD38low blasts
Naeem Khan et al.
BRITISH JOURNAL OF HAEMATOLOGY (2015)
Relation of Clinical Response and Minimal Residual Disease and Their Prognostic Impact on Outcome in Acute Myeloid Leukemia
Xueyan Chen et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Advancing the Minimal Residual Disease Concept in Acute Myeloid Leukemia
Peter Hokland et al.
SEMINARS IN HEMATOLOGY (2015)
Leukemic Stem Cell Frequency: A Strong Biomarker for Clinical Outcome in Acute Myeloid Leukemia
Monique Terwijn et al.
PLOS ONE (2014)
MRD-directed risk stratification treatment may improve outcomes of t(8;21) AML in the first complete remission: results from the AML05 multicenter trial
Hong-Hu Zhu et al.
BLOOD (2013)
Significance of minimal residual disease before myeloablative allogeneic hematopoietic cell transplantation for AML in first and second complete remission
Roland B. Walter et al.
BLOOD (2013)
Identification of emerging FLT3 ITD-positive clones during clinical remission and kinetics of disease relapse in acute myeloid leukaemia with mutated nucleophosmin
Tiziana Ottone et al.
BRITISH JOURNAL OF HAEMATOLOGY (2013)
Tumor heterogeneity makes AML a “moving target” for detection of residual disease
W. Zeijlemaker et al.
CYTOMETRY PART B-CLINICAL CYTOMETRY (2013)
Prognostic Relevance of Treatment Response Measured by Flow Cytometric Residual Disease Detection in Older Patients With Acute Myeloid Leukemia
Sylvie D. Freeman et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
High Prognostic Impact of Flow Cytometric Minimal Residual Disease Detection in Acute Myeloid Leukemia: Data From the HOVON/SAKK AML 42A Study
Monique Terwijn et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Flow cytometric quantification and immunophenotyping of leukemic stem cells in acute myeloid leukemia
Keumrock Hwang et al.
ANNALS OF HEMATOLOGY (2012)
Residual disease detected by multidimensional flow cytometry signifies high relapse risk in patients with de novo acute myeloid leukemia: a report from Children's Oncology Group
Michael R. Loken et al.
BLOOD (2012)
The surface molecule signature of primary human acute myeloid leukemia (AML) cells is highly associated with NPM1 mutation status
G. Tsykunova et al.
LEUKEMIA (2012)
The role of minor subpopulations within the leukemic blast compartment of AML patients at initial diagnosis in the development of relapse
C. Bachas et al.
LEUKEMIA (2012)
Clonal evolution in relapsed acute myeloid leukaemia revealed by whole-genome sequencing
Li Ding et al.
NATURE (2012)
Leukemia stem cells in 2010: Current understanding and future directions
Michael W. Becker et al.
BLOOD REVIEWS (2011)
Coexistence of LMPP-like and GMP-like Leukemia Stem Cells in Acute Myeloid Leukemia
Nicolas Goardon et al.
CANCER CELL (2011)
Human acute myelogenous leukemia stem cells are rare and heterogeneous when assayed in NOD/SCID/IL2R gamma c-deficient mice
Jean-Emmanuel Sarry et al.
JOURNAL OF CLINICAL INVESTIGATION (2011)
High Proportion of Leukemic Stem Cells at Diagnosis Is Correlated with Unfavorable Prognosis in Childhood Acute Myeloid Leukemia
Kai-Erik Witte et al.
PEDIATRIC HEMATOLOGY AND ONCOLOGY (2011)
High-frequency type I/II mutational shifts between diagnosis and relapse are associated with outcome in pediatric AML: implications for personalized medicine
Costa Bachas et al.
BLOOD (2010)
Leukemia-initiating cells from some acute myeloid leukemia patients with mutated nucleophosmin reside in the CD34- fraction
David C. Taussig et al.
BLOOD (2010)
Genomic, immunophenotypic, and NPM1/FLT3 mutational studies on 17 patients with normal karyotype acute myeloid leukemia (AML) followed by aberrant karyotype AML at relapse
Eunice S. Wang et al.
CANCER GENETICS AND CYTOGENETICS (2010)
Minimal residual disease in acute myeloid leukemia: already predicting a safe haven?
Gerrit Jan Schuurhuis et al.
EXPERT REVIEW OF HEMATOLOGY (2010)
Chemotherapy-resistant human AML stem cells home to and engraft within the bone-marrow endosteal region
Fumihiko Ishikawa et al.
NATURE BIOTECHNOLOGY (2007)
High stem cell frequency in acute myeloid leukemia at diagnosis predicts high minimal residual disease and poor survival
A van Rhenen et al.
CLINICAL CANCER RESEARCH (2005)
Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype.
B Falini et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
MRD parameters using immunophenotypic detection methods are highly reliable in predicting survival in acute myeloid leukaemia
N Feller et al.
LEUKEMIA (2004)
分享论文
